These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 31183768)

  • 1. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.
    Picardo S; Seow CH
    Drugs; 2019 Jul; 79(10):1053-1063. PubMed ID: 31183768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
    Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
    Gisbert JP; Chaparro M
    Drugs; 2020 Jul; 80(11):1085-1100. PubMed ID: 32562207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
    Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of biologic agents in pregnancy and breastfeeding.
    Horst S; Kane S
    Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
    Kiely CJ; Subramaniam K; Platten J; Pavli P
    Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
    Roseira J; Ramos J
    Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
    de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
    Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection.
    Mitsuya JB; Gonzalez R; Thomas R; El-Baba M
    J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):334-338. PubMed ID: 30247424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
    Lund T; Thomsen SF
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.
    Leung Y; Panaccione R; Ghosh S; Seow CH
    Can J Gastroenterol Hepatol; 2014 Oct; 28(9):505-9. PubMed ID: 25101334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?
    Chaparro M; Gisbert JP
    Expert Opin Drug Saf; 2014 Dec; 13(12):1749-62. PubMed ID: 25244582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.
    van Langenberg DR
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():10-1. PubMed ID: 26990680
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
    Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study.
    Borren NZ; Tan W; Jess AT; Li PM; Garber JJ; Luther J; Colizzo FP; Khalili H; Ananthakrishnan AN
    Dig Dis Sci; 2020 Dec; 65(12):3672-3678. PubMed ID: 32617768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.